DDInter790 DDInter1376
Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body. Furosemide has a fast onset and short duration of action and has been used safely and effectively in both pediatric and adult patients. The use of furosemide is particularly beneficial in clinical settings that require a drug with a higher diuretic potential. In addition to oral formulations, the solution for intravenous and intramuscular administration is also available, which is typically limited to patients who are unable to take oral medication or for patients in emergency clinical situations.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Furosemide {u} (Compound) resembles {v} (Compound) Indapamide
Furosemide {u} (Compound) treats {v} (Disease) coronary artery disease
Furosemide {u} (Compound) binds {v} (Gene) SLC22A11
Furosemide {u} (Compound) palliates {v} (Disease) chronic kidney failure
Furosemide {u} (Compound) is included by {v} (Pharmacologic Class) Increased Diuresis at Loop of Henle
Furosemide {u} (Compound) causes {v} (Side Effect) Epigastric discomfort
Furosemide (Compound) resembles Indapamide (Compound)
Furosemide (Compound) treats coronary artery disease (Disease)
Furosemide (Compound) binds SLC22A11 (Gene)
Furosemide (Compound) palliates chronic kidney failure (Disease)
Furosemide (Compound) is included by Increased Diuresis at Loop of Henle (Pharmacologic Class)
Furosemide (Compound) causes Epigastric discomfort (Side Effect)